Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and akt suppression

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1177-1184

  Shao, Yimin ^a   Yuan, Geheng ^a   Zhang, Junqing ^a   Guo, Xiaohui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

AMP activated protein kinase; Lipogenesis; Liraglutide; Visceral adipose tissue

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; COMPLEMENTARY DNA; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIRAGLUTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; RNA; LIPID;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DNA SYNTHESIS; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIDIDYMIS FAT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INTRAABDOMINAL FAT; LIPOGENESIS; LIPOGENETIC SIGNAL; MALE; MOUSE; NONHUMAN; OMENTAL ADIPOSE TISSUE; PERIRENAL ADIPOSE TISSUE; PROTEIN EXPRESSION; RNA ISOLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; METABOLISM; MUTANT MOUSE STRAIN; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENZYME ACTIVATION; INJECTIONS, SUBCUTANEOUS; INTRA-ABDOMINAL FAT; LIPIDS; LIRAGLUTIDE; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923210591     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S79175     Document Type: Article

References (43)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med. 2007;356 (3):213-215.
2. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106 (4):473-481.
3. Kopelman PG. Obesity as a medical problem. Nature. 2000;404 (6778):635-643.
4. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289 (1):76-79.
5. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89 (6):2583-2589.
6. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30 (1):162-172.
7. Tarui S, Tokunaga K, Fujioka S, Matsuzawa Y. Visceral fat obesity: anthropological and pathophysiological aspects. Int J Obes. 1991;15 Suppl 2:1-8.
8. Piernas C, Hernández-Morante JJ, Canteras M, Zamora S, Garaulet M. New computed tomography-derived indices to predict cardiovascular and insulin-resistance risks in overweight/obese patients. Eur J Clin Nutr. 2009;63 (7):887-897.
9. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011;12 (11):722-734.
10. Farmer SR. Regulation of PPARgamma activity during adipogenesis. Int J Obes (Lond). 2005;29 Suppl 1:S13-S16.
11. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4 (4):263-273.
12. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci. 2004;29 (1):18-24.
13. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase-development of the energy sensor concept. J Physiol. 2006;574 ({t 1):7-15.
14. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem. 1997;246 (2):259-273.
15. Sponarova J, Mustard KJ, Horakova O, et al. Involvement of AMP-activated protein kinase in fat depot-specific metabolic changes during starvation. FEBS Lett. 2005;579 (27):6105-6110.
16. Daval M, Foufelle F, Ferre P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol. 2006;574 (Pt 1):55-62.
17. Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem. 2005;280 (26):25250-25257.
18. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101 (3):515-520.
19. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56 (2):117-126.
20. Imeryüz N, Yeğen BC, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273 (4 Pt 1):G920-G927.
21. Meier JJ, Nauck MA. The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs. 2004;5 (4):402-410.
22. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45 (2):195-202.
23. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26 (3):268-278.
24. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32 (1):84-90.
25. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373 (9662):473-481.
26. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32 (7):1224-1230.
27. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52 (10):2046-2055.
28. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374 (9683):39-47.
29. Inoue K, Maeda N, Kashine S, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:109.
30. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11 (12):1163-1172.
31. Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15 (3):204-212.
32. Nakae J, Kitamura T, Kitamura Y, Biggs WH 3rd, Arden KC, Accili D. The forkhead transcription factor FoxO1 regulates adipocyte differentiation. Dev Cell. 2003;4 (1):119-129.
33. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9 (5):407-416.
34. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118 (3):829-838.
35. Gaidhu MP, Anthony NM, Patel P, Hawke TJ, Ceddia RB. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol Cell Physiol. 2010;298 (4):C961-C971.
36. Martínez-Agustin O, Hernández-Morante JJ, Martínez-Plata E, Sánchez de Medina F, Garaulet M. Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity. Regul Pept. 2010;163 (1-3):31-36.
37. Gauthier MS, O’Brien EL, Bigornia S, et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun. 2011;404 (1):382-387.
38. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007;403 (1):139-148.
39. Lin F, Ribar TJ, Means AR. The Ca2+/calmodulin-dependent protein kinase kinase, CaMKK2, inhibits preadipocyte differentiation. Endocrinology. 2011;152 (10):3668-3679.
40. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav. 2010;100 (5):503-510.
41. Nogueiras R, Pérez-Tilve D, Veyrat-Durebex C, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009;29 (18):5916-5925.
42. Park H, Kaushik VK, Constant S, et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 2002;277 (36):32571-32577.
43. Kim KY, Baek A, Hwang JE, et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 2009;69 (9):4018-4026.